opening: health 2.0 seoul chapter's first event

THE FIRST EVENTwith KiMES2013

COEX March 24, 2013SEOUL

09:00 ~ 09:30 / 등록 및 네트워킹09:30 ~ 10:00 / Opening: Health 2.0 Seoul Chapter / 김보람 창립자(Health 2.0 Seoul Chapter)10:00 ~ 10:30 / Consumer Health Startup Trends 2013 / 정지훈 교수(명지병원)10:30 ~ 11:00 / Special Lecture: 친환경시대, Green+Hospital 전략11:00 ~ 11:20 / Smart Patient: 스마트폰 시대 환자들의 새로운 검색, 커뮤니케이션 문화와 대응방안 / 임진석 대표(굿닥)11:20 ~ 11:40 / Casual Health Game - 건강한 강아지 순돌이 / 박재범 대표(휴레이포지티브)11:40 ~ 12:00 / Mobile Wellness Technology, Our Lessons and How We are Changing the World / 정세주 대표(눔)12:00 ~ 12:20 / Cloud 기반의 Animation 설명처방, HiChart / 정희두 대표(헬스웨이브)12:20 ~ 13:00 / Panel Discussion: Consumer Health Startups in Korea / 발표자 외 김정은 교수(서울대학교), 고영하 회장(한국엔젤투자협회)

Consumer Health Startups in Korea

DATE/TIME: March 24, 2013 09:00am - 01:00pmVENUE: COEX Conference Room #308REGISTRATION: http://bit.ly/Health2KiMES

THE FIRST EVENTwith KiMES2013

COEX March 24, 2013SEOUL

James G. Boram Kim

Source: Ludwig Gatzke and Markus Angermeier

COEX

Web 2.0: O’Reilly’s Core Competencies

• Services, not packaged software

• Data sources that get richer as more people use them

• Trusting users as co-developers

• Harnessing collective intelligence

• Leveraging the long tail through customer self-service

• Software above the level of a single device

• Lightweight user interfaces, and development and business models

Source: Tim O’Reilly, What is Web 2.0, September, 2005

vs.

COEX

Source: Enoch Choi

COEX

, the movement, is all about new technologies improving health care, including cloud, Web, mobile and sensors. Health 2.0 has three de!ning characteristics:1. Adaptable technology that integrates with the wider cloud and “unplatform” ecosystem

2. A focus on the user-experience through design and usability

3. The use of data to improve outcomes through intelligent decision-making

“... social software and light-weight tools to promote collaboration between ... stakeholders in health.” - Jane Sarasohn-Kahn and Matthew Holt

“... all the constituents focus on health care value ... for improving the safety, efficiency, and quality of health care.” - Scott Shreeve

“Health 2.0 is participatory healthcare. ...,we the patients can be effective partners in our own healthcare ...” - Ted Eytan

Source: Health 2.0 Wiki

COEX

Matthew Holt’s evolving view of a moving target

• Personalized search that looks into the long tail, but cares about the user experience

• Communities that capture the accumulated knowledge of patients and caregivers; and clinicians -- and explain it to the world

• Intelligent tools for content delivery -- and transactions

• Better integration of data with content

Source: Health 2.0 Wiki

All with the result of patients increasingly guiding their own care

COEX

Health 2.0: User-Generated Healthcare

Source: Matthew Halt

Search

SocialNetworks

Tools

COEX

Health 2.0: User-Generated Healthcare


Search

SocialNetworks

Tools

TransactionData

Content

COEX

A Continuum of Health 2.0


User-generatedhealth care

Users connectto providers

Partnerships toreform delivery

Data drivesdecisions & discovery

COEX

A Continuum of Health 2.0


User-generatedhealth care

Users connectto providers

Partnerships toreform delivery

Data drivesdecisions & discovery

Original Paper

Mining Online Social Network Data for Biomedical Research: AComparison of Clinicians’ and Patients’ Perceptions AboutAmyotrophic Lateral Sclerosis Treatments

Carlos Nakamura1, PhD; Mark Bromberg2, MD, PhD; Shivani Bhargava3, BA; Paul Wicks3, PhD; Qing Zeng-Treitler1,PhD1Department of Biomedical Informatics, University of Utah, Salt Lake City, UT, United States2Department of Neurology, University of Utah, Salt Lake City, UT, United States3PatientsLikeMe, Cambridge, MA, United States

Corresponding Author:Carlos Nakamura, PhDDepartment of Biomedical InformaticsUniversity of UtahRoom 5775 HSEB26 South 2000 EastSalt Lake City, UT, 84112-5775United StatesPhone: 1 801 213 3357Fax: 1 801 581 4297Email: [email protected]

AbstractBackground: While only one drug is known to slow the progress of amyotrophic lateral sclerosis (ALS), numerous drugs canbe used to treat its symptoms. However, very few randomized controlled trials have assessed the efficacy, safety, and side effectsof these drugs. Due to this lack of randomized controlled trials, consensus among clinicians on how to treat the wide range ofALS symptoms and the efficacy of these treatments is low. Given the lack of clinical trials data, the wide range of reportedsymptoms, and the low consensus among clinicians on how to treat those symptoms, data on the prevalence and efficacy oftreatments from a patient’s perspective could help advance the understanding of the symptomatic treatment of ALS.Objective: To compare clinicians’ and patients’ perspectives on the symptomatic treatment of ALS by comparing data from atraditional survey study of clinicians with data from a patient social network.Methods: We used a survey of clinicians’ perceptions by Forshew and Bromberg as our primary data source and adjusted thedata from PatientsLikeMe to allow for comparisons. We first extracted the 14 symptoms and associated top four treatments listedby Forshew and Bromberg. We then searched the PatientsLikeMe database for the same symptom–treatment pairs. ThePatientsLikeMe data are structured and thus no preprocessing of the data was required.Results: After we eliminated pairs with a small sample, 15 symptom–treatment pairs remained. All treatments identified asuseful were prescription drugs. We found similarities and discrepancies between clinicians’ and patients’ perceptions of treatmentprevalence and efficacy. In 7 of the 15 pairs, the differences between the two groups were above 10%. In 3 pairs the differenceswere above 20%. Lorazepam to treat anxiety and quinine to treat muscle cramps were among the symptom–treatment pairs withhigh concordance between clinicians’ and patients’ perceptions. Conversely, amitriptyline to treat labile emotional effect andoxybutynin to treat urinary urgency displayed low agreement between clinicians and patients.Conclusions: Assessing and comparing the efficacy of the symptomatic treatment of a complex and rare disease such as ALSis not easy and needs to take both clinicians’ and patients’ perspectives into consideration. Drawing a reliable profile of treatmentefficacy requires taking into consideration many interacting aspects (eg, disease stage and severity of symptoms) that were notcovered in the present study. Nevertheless, pilot studies such as this one can pave the way for more robust studies by helpingresearchers anticipate and compensate for limitations in their data sources and study design.

(J Med Internet Res 2012;14(3):e90) doi:10.2196/jmir.2127

J Med Internet Res 2012 | vol. 14 | iss. 3 | e90 | p.1http://www.jmir.org/2012/3/e90/(page number not for citation purposes)

Nakamura et alJOURNAL OF MEDICAL INTERNET RESEARCH

XSL•FORenderX

COEX

Source: Pew Internet & American Life Project

COEX

, the conference series, is the leading showcase of the new technologies transforming health care across the globe.With conferences in the U.S., Asia, Middle East and Europe, Health 2.0 provides the premier opportunities for connecting IT innovators to established healthcare organizations and investors.

COEX

Chapters represent the grassroots of Health 2.0!There is signi!cant work going on in healthcare IT, especially at the local level. Health 2.0 Chapters are free self-su!cient groups that bring home the bene!ts of a Health 2.0 conference to a more accessible level. Chapter leaders volunteer to help organize these exciting events to bring together their local community on a regular basis to network, learn, listen to speakers discuss relevant topics or see the latest demos from local companies. All of these groups serve a valuable role in bringing healthcare system professionals together in a local forum.

COEX

Like Us! Follow Us!

@Health2Seoul#H2Seoul

http://www.facebook.com/Health2Seoul

COEX

We thank our generous partners

opening: health 2.0 seoul chapter's first event

Health & Medicine